Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.915 USD | +1.13% | +2.29% | -44.58% |
04-29 | Prime Medicine Shares Jump After Application for Chronic Granulomatous Disease Treatment Gets FDA Clearance | MT |
04-29 | Prime Medicine Gets FDA Clearance for PM359 IND Application | DJ |
Sales 2024 * | 14.43M 19.86M | Sales 2025 * | 14.72M 20.25M | Capitalization | 560M 771M |
---|---|---|---|---|---|
Net income 2024 * | -218M -300M | Net income 2025 * | -223M -307M | EV / Sales 2024 * | 31.3 x |
Net cash position 2024 * | 109M 150M | Net cash position 2025 * | 275M 379M | EV / Sales 2025 * | 19.4 x |
P/E ratio 2024 * |
-2.63
x | P/E ratio 2025 * |
-3
x | Employees | 234 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 74.98% |
Latest transcript on Prime Medicine, Inc.
1 day | +1.03% | ||
1 week | +2.29% | ||
Current month | -29.86% | ||
1 month | -27.37% | ||
3 months | -27.69% | ||
6 months | -15.64% | ||
Current year | -44.58% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 70 | 20-06-30 | |
Allan Reine
DFI | Director of Finance/CFO | 49 | 01-16 |
Chief Operating Officer | 52 | 22-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 64 | 21-11-30 | |
Robert Nelsen
BRD | Director/Board Member | 60 | 20-08-31 |
Michael Kelly
BRD | Director/Board Member | 67 | 21-10-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.71% | 2 M€ | -25.75% | ||
0.00% | 9 M€ | +5.66% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 4.915 | +1.13% | 979 183 |
24-04-29 | 4.86 | +9.83% | 1,268,471 |
24-04-26 | 4.425 | +2.91% | 641,595 |
24-04-25 | 4.3 | -8.51% | 848,913 |
24-04-24 | 4.7 | -2.08% | 522,474 |
Delayed Quote Nasdaq, April 30, 2024 at 03:55 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.58% | 560M | |
-3.67% | 102B | |
+1.51% | 96.29B | |
+2.13% | 22.18B | |
-15.91% | 21.2B | |
-9.21% | 18.31B | |
-39.98% | 17.38B | |
-14.61% | 16.36B | |
+4.55% | 13.97B | |
+31.72% | 12.17B |
- Stock Market
- Equities
- PRME Stock